The health care spending debate in our country raises the following questions: How much spending is too much? What percentage of the gross domestic product should be spent on health care? How can the value of the health care dollar be maximized? As stakeholders wrestle with these questions, significant attention is often paid to the portion of spending attributable to various sectors of the health care system. The Trump administration has focused heavily on prescription medicines.
As health care stakeholders engage in public dialogue on this topic and consider policies for managing prescription drug spending, there is a need for sound data to inform the discussions. How much are we spending on drugs? If you ask a multi-stakeholder panel of health care leaders, you’ll likely hear a range of responses, from a low of 10% to a high of nearly 30%. If stakeholders are unable to agree on a number, they are unable to even begin to agree on a policy. Can these seemingly irreconcilable responses be reconciled?
The answer is yes! AcademyHealth and NPC hosted an interactive webinar on June 18 at 2 p.m. ET to understand the underlying differences in these estimates and how to address them to set the stage for a collaborative and evidence-based policy discussion.
- Robert W. Dubois, MD, PhD, Chief Science Officer and Executive Vice President, National Pharmaceutical Council
- Michael Kleinrock, MA, Research Director, IQVIA Institute for Human Data Science
- Lisa Simpson, MB, BCh, MPH, FAAP, President and CEO, AcademyHealth (Moderator)